Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
At Vive Ageless Weight Loss Center, your health and safety are our top priorities
Key Takeaways AOD 9604 produces 2-3 times greater fat loss than placebo in clinical trials with women Standard dosing ranges from 0.5mg to 1mg daily via subcutaneous injection Side effects occur in fewer than 5% of women, primarily mild injection site reactions Results typically become visible after 4-6 weeks of consistent daily administration The peptide preserves lean muscle mass while specifically targeting fat tissue How AOD 9604 Works for Female Fat Loss AOD 9604 functions by activating beta-3 adrenergic receptors in adipose tissue, specifically triggering lipolysis without the growth-promoting effects of full-length growth hormone
They aren't alternatives to each other they're complementary research tools that address different research questions
Systemic Use Systemic or injectable use should never occur without medical oversight and established clinical evidence
PMC2431115 FDA compounding-pathway status the 503A bulk drug substances process, the July 2324, 2026 PCAC agenda for BPC-157, KPV, and TB-500, route-specific questions for injectable GHK-Cu, and the planned GHK-Cu review: FDA 503A bulk drug substances update
Symptoms such as muscle tremors and abnormal movements have been observed, but these effects typically resolve with appropriate management and follow-up
US$ 24.80
US$ 24.27
US$ 23.06
US$ 28.70
